

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of all claims in the application.

Listing of Claims

1 - 87. (Cancelled)

88. (Previously Presented) An antibody or immunoadhesin, said antibody or immunoadhesin comprising an amino acid substitution selected from the group consisting of 239D, 239E, 239Q, and 239T, wherein said antibody or immunoadhesin increases binding affinity to an FcγR as compared to its parent antibody or immunoadhesin, and wherein numbering is according to the EU index.

89. (Previously Presented) An antibody or immunoadhesin, said antibody or immunoadhesin comprising an amino acid substitution selected from the group consisting of 239D, 239E, 239N, 239Q, 239F, 239T, 239H and 239Y, wherein numbering is according to the EU index.

90. (Previously Presented) An antibody or immunoadhesin, said antibody or immunoadhesin comprising an amino acid substitution from the group consisting of 239D, 239E, 239Q, and 239T, wherein said antibody or immunoadhesin further comprises an amino acid substitution at a position selected from the group consisting of 234, 235, 240, 241, 243, 244, 245, 247, 256, 262, 263, 264, 265, 266, 267, 269, 270, 290, 296, 297, 298, 299, 312, 313, 322, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334 and 339, wherein said antibody or immunoadhesin increases binding affinity to an FcγR as compared to its parent antibody or immunoadhesin, wherein numbering is according to the EU index.

91. (Previously Presented) An antibody or immunoadhesin of a parent Fc polypeptide, said antibody or immunoadhesin comprising an amino acid substitution selected from the group consisting of 239D, 239E, 239N, 239Q, 239F, 239T, 239H and 239Y, wherein said antibody or immunoadhesin further comprises an amino acid substitution at a position selected from the group consisting of 234, 235, 240, 241, 243, 244, 245, 247, 256, 262, 263, 264, 265, 266, 267,

269, 270, 290, 296, 297, 298, 299, 312, 313, 322, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334 and 339, wherein numbering is according to the EU index.

92. (Previously Presented) An antibody or immunoadhesin-of a parent Fc polypeptide, said antibody or immunoadhesin comprising an amino acid substitution selected from the group consisting of 239D, 239E, 239N, 239Q, 239F, 239T, 239H and 239Y, wherein said antibody or immunoadhesin further comprises an amino acid substitution at position 332, wherein numbering is according to the EU index.

93. (Cancelled)

94. (Previously Presented) An antibody or immunoadhesin according to claim 92 wherein said substitution at position 332 is selected from the group consisting of I332D, I332E, I332N, I332Q, I322T, I332H, I332Y, and I332A.

95. (Previously Presented) An antibody or immunoadhesin according to claim 92 comprising the amino acid substitutions 239D and 332E.

96. (Previously Presented) An antibody or immunoadhesin-of a parent Fc polypeptide, said antibody or immunoadhesin comprising an amino acid substitution at position 239 selected from the group consisting of 239D, 239E, 239Q, and 239T, wherein said antibody or immunoadhesin further comprises an amino acid substitution selected from the group consisting of 234D, 234E, 234N, 234Q, 234T, 234H, 234Y, 234I, 234V, 234F, 235D, 235S, 235N, 235Q, 235T, 235H, 235Y, 235I, 235V, 235F, 240I, 240A, 240T, 240M, 241W, 241L, 241Y, 241E, 241R, 243W, 243L, 243Y, 243R, 243Q, 244H, 245A, 247V, 247G, 262I, 262A, 262T, 262E, 263I, 263A, 263T, 263M, 264L, 264I, 264W, 264T, 264R, 264F, 264M, 264Y, 264E, 265G, 265N, 265Q, 265Y, 265F, 265V, 265I, 265L, 265H, 265T, 266I, 266A, 266T, 266M, 267Q, 267L, 269H, 269Y, 269F, 269R, 296E, 296Q, 296D, 296N, 296S, 296T, 296L, 296I, 296H, 297S, 297D, 297E, 298H, 299I, 299L, 299A, 299S, 299V, 299H, 299F, 299E, 313F, 325Q, 325L, 325I, 325D, 325E, 325A, 325T, 325V, 325H, 327N, 327L, 328M, 328D, 328E, 328N, 328Q, 328F, 328I, 328V, 328T,

328H, 328A, 329F, 330L, 330Y, 330V, 330I, 330F, 330R, 330H, 332D, 332E, 332N, 332Q, 322T, 332H, 332Y, and 332A, wherein numbering is according to the EU index.

97. (Previously Presented) An antibody or immunoadhesin of a parent Fc polypeptide, said antibody or immunoadhesin comprising an amino acid substitution selected from the group consisting of 239D, 239E, 239N, 239Q, 239F, and 239T, 239H and 239Y, wherein said antibody or immunoadhesin further comprises an amino acid substitution selected from the group consisting of 234D, 234E, 234N, 234Q, 234T, 234H, 234Y, 234I, 234V, 234F, 235D, 235S, 235N, 235Q, 235T, 235H, 235Y, 235I, 235V, 235F, 240I, 240A, 240T, 240M, 241W, 241L, 241Y, 241E, 241R, 243W, 243L, 243Y, 243R, 243Q, 244H, 245A, 247V, 247G, 262I, 262A, 262T, 262E, 263I, 263A, 263T, 263M, 264L, 264I, 264W, 264T, 264R, 264F, 264M, 264Y, 264E, 265G, 265N, 265Q, 265Y, 265F, 265V, 265I, 265L, 265H, 265T, 266I, 266A, 266T, 266M, 267Q, 267L, 269H, 269Y, 269F, 269R, 296E, 296Q, 296D, 296N, 296S, 296T, 296L, 296I, 296H, 297S, 297D, 297E, 298H, 299I, 299L, 299A, 299S, 299V, 299H, 299F, 299E, 313F, 325Q, 325L, 325I, 325D, 325E, 325A, 325T, 325V, 325H, 327N, 327L, 328M, 328D, 328E, 328N, 328Q, 328F, 328I, 328V, 328T, 328H, 328A, 329F, 330L, 330Y, 330V, 330I, 330F, 330R, 330H, 332D, 332E, 332N, 332Q, 322T, 332H, 332Y, and 332A, wherein numbering is according to the EU index.

98. (Previously Presented) An antibody or immunoadhesin according to claim 88 or 89 which is selected from the group consisting of 239E/332E, 239Q/332E, 239E/265G, 239E/265N, 239E/265Q, 239D/332D, 239D/332E, 239D/332N, 239D/332Q, 239E/332D, 239E/332N, 239E/332Q, 239N/332D, 239N/332E, 239N/332N, 239N/332Q, 239Q/332D, 239Q/332N, 239Q/332Q, 239E/264I/332E, 239Q/264I/332E, 239E/264I/330Y/332E, 239E/264I/298A/330Y/332E, 239D/297D/332E, 239E/297D/332E, 239D/265V/297D/332E, 239D/265I/297D/332E, 239D/265L/297D/332E, 239D/265F/297D/332E, 239D/265Y/297D/332E, 239D/265H/297D/332E, 239D/265T/297D/332E, 239N/330Y/332E, 239D/330L/332E, 239N/330L/332E, 264I/298A/332E, 239D/298A/332E, 239N/298A/332E, 239D/264I/332E, 239D/264I/298A/332E, 332E/239D/298A, 239D/330Y/332E and 239D/264I/330L/332E.

99. (Previously Presented) An antibody or immunoadhesin according to claim 98 which is 239D/332E.

100. (Previously Presented) An antibody or immunoadhesin according to claim 98 which is 239D/332E/330Y.

101. (Previously Presented) An antibody or immunoadhesin according to claim 98 which is 239D/332E/330L.

102. (Previously Presented) An antibody or immunoadhesin according to claim 98 which is 239D/332E/298A.

103. (Previously Presented) An antibody or immunoadhesin of a parent Fc polypeptide, said antibody or immunoadhesin comprising an amino acid substitution selected from the group consisting of 239D, 239E, 239N, 239Q, 239F, and 239T, 239H and 239Y, wherein said antibody or immunoadhesin increases binding affinity to an FcγR as compared to said its parent polypeptide antibody or immunoadhesin, wherein numbering is according to the EU index.

104. (Previously Presented) An antibody or immunoadhesin according to claim 103 wherein said FcγR is FcγRIIIa.

105. (Previously Presented) An antibody or immunoadhesin according to claim 104 wherein said FcγRIIIa is a V158 or F158 allotype of FcγRIIIa.

106. (Previously Presented) An antibody or immunoadhesin according to any of claims 88-92 and 96-97 wherein said substitution is 239D.

107. (Previously Presented) An antibody or immunoadhesin according to any of claims 88-92 and 96-97 wherein said substitution is 239E.

108. (Previously Presented) An antibody or immunoadhesin according to any of claims 88-92 and 96-97 wherein said antibody or immunoadhesin is an antibody.

109. (Previously Presented) An antibody according to claim 108 wherein said antibody is selected from the group consisting of a human antibody, a humanized antibody, and a monoclonal antibody.

110. (Withdrawn – Previously Presented) An antibody or immunoadhesin according to any of claims 88-92 and 96-97 wherein said antibody or immunoadhesin further comprises an engineered glycoform.

111. (Previously Presented) An antibody or immunoadhesin according to any of claims 88-92 and 96-97 wherein said antibody or immunoadhesin has specificity for a target antigen selected from the group consisting of CD19, CD20, CD22, CD30, CD33, CD40, CD40L, CD52, Her2/neu, EGFR, EpCAM, MUC1, GD3, CEA, CA 125, HLA-DR, TNFalpha, MUC18, prostate specific membrane antigen (PMSA) and VEGF.

112. (Previously Presented) A composition comprising the antibody or immunoadhesin according to any of claims 88-9392 and 96-97 further comprising a pharmaceutically acceptable carrier.

Please cancel claims 113 to 134 without prejudice or disclaimer.

135. (Previously Presented) An antibody or immunoadhesin comprising a 239D amino acid substitution, wherein said numbering is according to the EU index.

136. (Previously Presented) An antibody or immunoadhesin comprising a 239E amino acid substitution, wherein said numbering is according to the EU index.

137. (Previously Presented) An antibody or immunoadhesin according to claim 135 or 136 wherein said antibody or immunoadhesin increases binding affinity to an FcγR as compared to its parent antibody or immunoadhesin.

Please cancel claims 138 without prejudice or disclaimer.

139. (New) A protein comprising an Fc variant of a parent Fc polypeptide comprising an amino acid modification in the Fc region of said parent Fc polypeptide selected from the group consisting of 239D and 239E, wherein said protein increases binding affinity to an FcγR as compared to said parent Fc polypeptide, wherein numbering is according to the EU index.

140. (New) A protein comprising an Fc variant of a parent Fc polypeptide comprising an amino acid modification in the Fc region of said parent Fc polypeptide, selected from the group consisting of 239D and 239E, wherein numbering is according to the EU index.

141. (New) A protein comprising an Fc variant of a parent Fc polypeptide comprising an amino acid modification in the Fc region of said parent Fc polypeptide selected from the group consisting of 239D, 239E, 239N, 239Q, 239F, 239T, 239H and 239Y, wherein said protein further comprises an amino acid substitution at position 332, wherein numbering is according to the EU index.

142. (New) A protein according to claim 139, 140 or 141 wherein said protein is an antibody.

143. (New) A protein according to claim 142 wherein said antibody further comprises an engineered glycoform.

144. (New) A composition comprising the protein of claim 139, 140, 141 or 143 further comprising a pharmaceutically acceptable carrier.